Professor / Hematologist
Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino, Italy
Dr. Francesca Gay is Associate Professor in the University of Torino, Department of Molecular Biotechnology and Health Sciences, and works as hematologist at the Division of Hematology 1, and SSD Clinical trials in onco-ematology and multiple myeloma, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. She completed her medical degree in 2004 and her fellowship in hematology in 2008 at the University of Torino, Italy. She obtained her PhD in Medicine and Experimental Therapy in 2014.
She is a member of ASH, EHA, ESMO, EMN, IMS, and SIE. She is a member of the EHA Steering Commettee Program and has previously been a member of the EHA Steering Commettee Program Advisory Board, of the ESMO Clinical Practice Guidelines committee, of the EMN Young Board, of the IMS Board and the Educational Commettee . She is involved in the design, development and coordination of phase I/II/III clinical trials for the treatment of multiple myeloma in tight collaboration with the European Myeloma Network, and principal investigator in multicenter trials. She worked on several international multicenter projects and data analyses.
Dr. Gay’s main research focuses on the diagnosis and the clinical and experimental treatment of patients with multiple myeloma and associated disorders, particularly of newly diagnosed patients eligible for autologous stem-cell transplantation. Her interests also include the use of new biological molecules, monoclonal antibodies, immunotherapeutic agents, CAR T Cells and stem-cell transplantation techniques.
She is author and co-author of more than 100 papers published in peer reviewed journals, as well as reviewer for several journals including Lancet, Leukemia, Lancet Oncology, Lancet Hematology, Blood Cancer Journal and Haematologica. In 2019 she has been awarded the Bart Barlogie Young Investigator Award by the International Myeloma Society and in 2022 of the CoMy woman in multiple myeloma achievement award.